Medical and Scientific Evidence Linking Dupixent to Cutaneous T-Cell Lymphoma

Medical and Scientific Evidence Linking Dupixent to Cutaneous T-Cell Lymphoma

Patients and families have asked whether there is credible, medical and scientific evidence linking Dupixent to cutaneous T-cell lymphoma (CTCL). Over the past several years, peer-reviewed studies, pharmacovigilance analyses, and case reports have identified a concerning signal: some individuals treated with dupilumab (brand name Dupixent) for presumed inflammatory skin disease later received a diagnosis of CTCL-or experienced acceleration of previously unrecognized lymphoma. While no single study proves causation, the pattern is significant enough that the U.S. Food and Drug Administration (FDA) has formally listed CTCL as a potential safety signal for Dupixent and is evaluating whether regulatory action is needed.

CTCL is rare and often resembles eczema in its early stages. That overlap can delay the right diagnosis, particularly when patients are started on a potent biologic that changes immune signaling in the skin. Multiple clinical series now describe patients whose rashes worsened or evolved atypically after starting dupilumab, prompting biopsies that revealed mycosis fungoides or Sézary syndrome, the two most common CTCL subtypes.

What the FDA’s Safety Signal Means-and Why It Matters

On March 31, 2025, the FDA’s quarterly FAERS report added “Dupixent (dupilumab) – Cutaneous T-cell lymphoma” to its list of Potential Signals of Serious Risks/New Safety Information. In that same entry, the FDA states it is “evaluating the need for regulatory action.” This is an official, public safety signal-not a final conclusion, but a formal notice that the agency has seen enough reports to warrant closer review.

The FDA’s Potential Signals list is built from FAERS (the agency’s Adverse Event Reporting System) and is updated quarterly. Placement on the list indicates a potential association that needs further assessment; it may lead to label changes, safety communications, or other regulatory measures if the signal holds up under scrutiny. For Dupixent and CTCL, this entry corroborates growing clinical literature that has described new-onset diagnoses or disease acceleration after therapy initiation.

For patients and prescribers, the safety signal serves as an early warning to maintain a high index of suspicion when skin disease behaves atypically on dupilumab-particularly if it fails to respond as expected or progresses despite treatment. It is precisely in those scenarios that clinicians in published reports have discovered an underlying lymphoma.

Peer-Reviewed Studies Quantifying the Risk: What Researchers Found

Several independent groups have tried to quantify whether dupilumab users face a higher relative risk of CTCL compared to non-users with similar conditions. In a 2024 retrospective cohort published in the Journal of the American Academy of Dermatology, researchers reported an approximately four-fold increased odds of CTCL among atopic dermatitis patients treated with dupilumab (odds ratio ~4.1; 95% CI ~2.1-8.2). Although observational and subject to confounding, the signal was statistically significant and has been widely discussed in the dermatology community.

A 2024 analysis in a peer-reviewed venue likewise reported an increased relative risk of CTCL among dupilumab-treated patients, reinforcing concerns raised by clinicians at the bedside. While methodologies and datasets differ across studies, the convergence around a non-trivial association has pushed the conversation from isolated anecdotes to a pattern that warrants caution.

Importantly, not all research concludes there is a definitive causal link-some reviews emphasize that the overall malignancy profile for dupilumab remains reassuring except for the CTCL signal, which appears to be the outlier. That nuance is critical: it suggests a targeted concern for lymphoma of the skin, rather than a generalized cancer risk.

Pharmacovigilance and FAERS Analyses: The “Signal” Behind the Signal

Beyond single-center cohorts, several teams have mined FAERS to evaluate whether CTCL reports are disproportionately associated with dupilumab. These studies rely on disproportionality statistics-tools widely used in drug safety to flag unusual event patterns compared with background reporting. Multiple publications have identified a disproportionate reporting signal for CTCL with dupilumab, which aligns with the FDA’s decision to list CTCL as a potential safety issue for the drug.

Pharmacovigilance cannot prove causation; reports can be incomplete, biased, or confounded by misdiagnosis. Still, when the signal is consistent across analyses-and echoed by case series and cohort studies-it strengthens the argument that the association is real enough to merit clinical vigilance and regulatory attention.

Some authors have also compared adverse event profiles between adults and pediatric populations, exploring whether age modifies risk. Although pediatric CTCL remains rare, the adult-skewed signal is one more reason clinicians recommend thorough evaluation of persistent or evolving rashes in older dupilumab users.

Clinical Reports: How CTCL Can Be “Unmasked” on Dupilumab

Case reports and series offer a window into real-world presentations. Dermatologists have documented patients who began dupilumab for presumed eczema or prurigo nodularis, only to develop worsening plaques, tumors, or erythroderma. Subsequent biopsies and immunophenotyping revealed mycosis fungoides or Sézary syndrome. Several publications explicitly describe “acceleration” or “unmasking” of CTCL temporally related to dupilumab treatment.

A 2025 retrospective review and other clinical series collectively discuss dozens of such patients, noting that diagnoses often emerge within months to the first couple of years after therapy initiation-sometimes after an initial period of apparent improvement. These patterns have prompted calls for earlier biopsy when rashes on dupilumab show atypical features or fail to track with expected response.

One practical takeaway from these reports is not to assume treatment failure equals “more eczema.” When disease morphology changes, when pruritus intensifies despite dosing, or when new nodules or tumors appear, biopsy and hematologic consultation should be considered to rule out CTCL.

Possible Biological Rationale: Why the IL-4/IL-13 Axis Matters

Dupilumab blocks the IL-4 receptor alpha, inhibiting IL-4 and IL-13 signaling that drives type 2 inflammation in atopic dermatitis and other conditions. Several investigators have theorized that interrupting this pathway may alter the cutaneous immune environment in a way that permits expansion of pre-existing malignant T-cell clones or unmasks an indolent lymphoma by suppressing inflammatory camouflage. While still a working hypothesis, it offers a coherent framework that matches clinical observations.

This rationale does not mean dupilumab “causes” CTCL de novo in every instance. More plausibly, patients with undiagnosed early CTCL-clinically mimicking eczema-could experience disease evolution when type-2 signaling is modified. That is why careful baseline assessment and ongoing dermatologic surveillance are being emphasized in recent publications.

In short, the mechanistic story is still unfolding, but it aligns with the aggregate signal from FAERS, cohort data, and case reports, strengthening concern specifically around Dupixent lymphoma risk limited to CTCL rather than a broad cancer risk profile.

Red Flags Your Care Team Shouldn’t Ignore

Published case reports repeatedly mention clinical “red flags” that prompted biopsy and ultimately led to lymphoma diagnoses. If you or a loved one is on dupilumab, alert your clinician promptly if any of the following occur. These are not diagnostic by themselves, but they are reasons to re-evaluate.

• Rapidly evolving plaques, nodules, or tumors despite therapy
• Erythroderma (widespread redness) or new scaling patterns that don’t fit prior disease
• Persistent lymphadenopathy, fevers, night sweats, or unexplained weight loss
• Worsening pruritus without visible improvement in dermatitis
• Incongruent biopsy findings or atypical T-cell clonality on workup

From a practical standpoint, early biopsy and immunophenotyping can shorten the time to correct diagnosis. When CTCL is confirmed, timely referral to a multidisciplinary team (dermatology, hematology/oncology, pathology) helps align staging and treatment without delay.

If you’re reading this because your skin disease worsened on dupilumab, gather your medical records and photographs of the rash over time. This documentation can be crucial both for medical care and for assessing potential legal claims related to Dupixent CTCL.

What This Evidence Means for Potential Legal Claims

From a legal perspective, the combination of: (1) an FDA-posted potential safety signal regarding CTCL; (2) peer-reviewed cohort data showing elevated relative risk; (3) multiple pharmacovigilance studies with disproportionate CTCL reporting; and (4) consistent clinical case reports, forms a substantive evidentiary platform for claims alleging failure to warn or inadequate risk communication.

Potential damages in these cases typically include medical costs, lost wages, loss of earning capacity, pain and suffering, and where applicable, future care needs. The viability and value of a claim will turn on facts such as the timeline of symptoms, how long dupilumab was used, whether CTCL warning information was accessible to prescribers at the time, and what the manufacturer knew or should have known when marketing the drug. Dupilumab CTCL cases are fact-intensive and require detailed record review.

Mid-case support matters. If you believe Dupixent worsened or unmasked CTCL, speak with our team at Alonso Krangle, LLP for a free consultation-we can evaluate medical chronology, expert opinions, and the interplay between evolving scientific literature and your individual case. Call 800-403-6191 or submit our online form to begin a confidential review.

Who May Qualify to File a Dupixent CTCL Lawsuit

While every situation is unique, people in the following categories may be candidates for a legal claim tied to Dupixent lymphoma risk:

• Individuals diagnosed with mycosis fungoides or Sézary syndrome after starting dupilumab
• Patients initially treated for atopic dermatitis or prurigo nodularis whose disease rapidly worsened or evolved on therapy
• Patients whose diagnosis emerged within months to a few years of initiating dupilumab, particularly when biopsies were delayed due to presumed eczema
• Families who lost a loved one where CTCL progression temporally followed dupilumab use

Evidence that strengthens a claim includes: dermatology notes before and during treatment, pathology reports (including T-cell receptor studies), imaging, pharmacy records, and any communications about continued dupilumab despite atypical progression. Pharmacovigilance articles and FDA safety signals can help frame foreseeability and duty to warn.

Timelines matter. Courts often scrutinize whether a reasonable manufacturer would have investigated and communicated risks as signals matured in the literature and in FAERS. Having a clear chronology of symptoms, biopsies, and clinical decisions helps align the legal theory with the scientific record surrounding FDA safety signal Dupixent.

Practical Steps If You’re Worried About Dupixent and CTCL

First, coordinate with your treating clinicians. If your skin disease is not improving as expected-or if it’s changing in ways described above-ask whether repeat biopsy, flow cytometry, or hematology input is appropriate. Published reports show that early, thorough evaluation can change outcomes by moving patients onto the right therapy sooner.

Second, organize your records. Keep a treatment diary, save medication guides, and request pathology materials. These documents are essential both for safe medical care and for evaluating dupilumab CTCL cases for potential legal action.

Third, be mindful of statute-of-limitations issues that can vary by jurisdiction and may run from the time of diagnosis or discovery of the alleged injury. Our firm can help you assess deadlines and preserve your rights while you continue receiving medical care.

The Bottom Line on the Evidence-and How We Can Help

The signal linking Dupixent CTCL is no longer just a handful of anecdotes. The FDA has posted CTCL as a potential safety issue for dupilumab and is reviewing the need for regulatory action. Independent cohort data show elevated relative risk, multiple FAERS analyses detect a disproportionate CTCL signal, and real-world case reports repeatedly describe unmasking or acceleration after therapy begins. Together, these sources create a credible, actionable foundation for both medical vigilance and legal accountability.

If you or a loved one was diagnosed with mycosis fungoides or Sézary syndrome after using Dupixent, contact Alonso Krangle, LLP today. Our lawyers will review your medical timeline, coordinate expert evaluation, and pursue the compensation the law allows. Call 800-403-6191 or use our secure contact form to get started-confidentially and at no cost to you.